1. Search Result
Search Result
Results for "

MTA

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Natural
Products

2

Recombinant Proteins

1

Isotope-Labeled Compounds

2

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-RS19921

    Small Interfering RNA (siRNA) Others

    Mta1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mta1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mta1 Mouse Pre-designed siRNA Set A
    Mta1 Mouse Pre-designed siRNA Set A
  • HY-RS27290

    Small Interfering RNA (siRNA) Others

    Mta2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mta2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mta2 Rat Pre-designed siRNA Set A
    Mta2 Rat Pre-designed siRNA Set A
  • HY-RS08747

    Small Interfering RNA (siRNA) Others

    MTA2 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MTA2 Human Pre-designed siRNA Set A
    MTA2 Human Pre-designed siRNA Set A
  • HY-RS08748

    Small Interfering RNA (siRNA) Others

    MTA3 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MTA3 Human Pre-designed siRNA Set A
    MTA3 Human Pre-designed siRNA Set A
  • HY-RS20776

    Small Interfering RNA (siRNA) Others

    Mta2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mta2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mta2 Mouse Pre-designed siRNA Set A
    Mta2 Mouse Pre-designed siRNA Set A
  • HY-RS26423

    Small Interfering RNA (siRNA) Others

    Mta1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mta1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mta1 Rat Pre-designed siRNA Set A
    Mta1 Rat Pre-designed siRNA Set A
  • HY-RS08746

    Small Interfering RNA (siRNA) Others

    MTA1 Human Pre-designed siRNA Set A contains three designed siRNAs for MTA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MTA1 Human Pre-designed siRNA Set A
    MTA1 Human Pre-designed siRNA Set A
  • HY-174983

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-6 (Compound 31) is a selective MTA-cooperative PRMT5 inhibitor. PRMT5-MTA-IN-6 exhibits potent inhibitory activity against PRMT5・MTA (IC50: 6.6 nM). PRMT5-MTA-IN-6 selectively inhibits the growth of MTAP-deleted HCT-116 cells (IC50: 319 nM). PRMT5-MTA-IN-6 can be used in the research of MTAP-deleted tumors .
    PRMT5-MTA-IN-6
  • HY-176702

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-5 (Compound 7) is an orally active, irreversible PRMT5-MTA complex (PRMT5•MTA) inhibitor (IC50=1.15 nM). PRMT5-MTA-IN-5 blocks arginine methylation and inhibits ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-5 potently inhibits proliferation in MTAP-deficient tumor cells. PRMT5-MTA-IN-5 is promising for research of MTAP-deficient solid tumors, such as liver, breast, and pancreatic cancers .
    PRMT5-MTA-IN-5
  • HY-163799

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-1 (Compound A9a) is an inhibitor for protein arginine methyltransferase PRMT5-MTA. PRMT5-MTA-IN-1 inhibits the proliferation of colorectal cancer cell HCT116 wildtype and MTAP del mutant, with an IC50 of 16 nM and 2.47 μM. PRMT5-MTA-IN-1 exhibits good liver microsomal stability and film permeability. PRMT5-MTA-IN-1 exhibits good pharmacokinetic characteristics in CD-1 mice .
    PRMT5-MTA-IN-1
  • HY-162989

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-2 (compund 1) is a MTA co-inhibitor of PRMT5 with IC50 less than 1.5 nM .
    PRMT5-MTA-IN-2
  • HY-172733S

    Isotope-Labeled Compounds Histone Methyltransferase Cancer
    PRMT5-MTA-IN-3-d3 (compound P22) is the deuterium labeled PRMT5-MTA-IN-3 (HY-172733). PRMT5-MTA-IN-3-d3 is an orally active PRMT5-MTA inhibitor. PRMT5-MTA-IN-3-d3 has antiproliferative effects on HTC116-MTAP del and wild type colorectal cancer HCT-116 cell lines, with IC50 values of 6 nM and 961 nM, respectively. PRMT5-MTA-IN-3-d3 has anticancer effects, especially for MTAP-deficient tumors, such as non-small cell lung cancer (NSCLC), pancreatic cancer .
    PRMT5-MTA-IN-3-d3
  • HY-139611
    Navlimetostat
    3 Publications Verification

    MRTX-1719

    Histone Methyltransferase Cancer
    Navlimetostat is a potent, orally active, selective PRMT5•MTA complex inhibitor, with IC50 of 3.6 and 20.5 nM for PRMT5•MTA and PRMT5. Navlimetostat binds to the PRMT5•MTA complex, with KD value of 0.14 pM. Navlimetostat shows antineoplastic activity in vitro and in vivo, and can be used for cancer study .
    Navlimetostat
  • HY-176701

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC50=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC50=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .
    PRMT5-MTA-IN-4
  • HY-172733

    Histone Methyltransferase Cancer
    PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. PRMT5-MTA-IN-3 inhibits cell proliferation in the MTAP-deficient colorectal cancer HCT - 116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 is promising for research of cancers, especially for MTAP-deficient tumors, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer .
    PRMT5-MTA-IN-3
  • HY-139611B

    (S)-MRTX-1719

    Histone Methyltransferase Cancer
    (S)-Navlimetostat (example 16-7) is the S-enantiomer of Navlimetostat. (S)-Navlimetostat is a PRMT5/MTA complex inhibitor, with an IC50 of 7070 nM .
    (S)-Navlimetostat
  • HY-156680

    Histone Methyltransferase Cancer
    TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers .
    TNG-462
  • HY-163737

    Microtubule/Tubulin Cancer
    ST-401, a microtubule-targeting agent (MTA), is a brain-penetrant microtubule (MT) assembly inhibitor. ST-401 disrupts microtubule (MT) function through gentle and reverisible reduction in MT assembly that triggers mitotic delay and cell death in interphase. ST-401 shows a potent antitumor activity .
    ST-401
  • HY-139611C
    Navlimetostat hydrochloride
    3 Publications Verification

    MRTX-1719 hydrochloride

    Histone Methyltransferase Cancer
    Navlimetostat hydrochloride is a potent first-in-class selective inhibitor of the PRMT5/MTA complex, with an IC50 of less than 10 nM in PRMT5/MTA MTAP DEL SDMA cells .
    Navlimetostat hydrochloride
  • HY-138684

    Histone Methyltransferase Cancer
    MRTX9768 is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768
  • HY-138684A

    Histone Methyltransferase Cancer
    MRTX9768 hydrochloride is a potent, selective, orally active, first-in-class PRMT5-MTA complex inhibitor .
    MRTX9768 hydrochloride
  • HY-153390

    Histone Methyltransferase Cancer
    AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP .
    AMG-193
  • HY-153390A

    Histone Methyltransferase Cancer
    (R)-AMG-193 is an isomer of AMG 193 (HY-153390). AMG 193 is an orally active MTA-cooperative PRMT5 inhibitor with antitumor activity. AMG 193, when complexed with MTA, preferentially inhibits the growth of MTAP-deficient tumor cells by inhibiting PRMT5 (IC50=0.107 μM), thereby protecting normal cells with wild-type MTAP .
    (R)-AMG-193
  • HY-158143

    Histone Methyltransferase Cancer
    PRMT5-IN-34 (Compound C) is an inhibitor of MTA-cooperative Protein arginine methyltransferase 5 (PRMT5/MAT) .
    PRMT5-IN-34
  • HY-168842

    Histone Methyltransferase Cancer
    PRMT5-IN-47 (compound 20) is a potent, selectively and orally active, MTA cooperative PRMT5 inhibitor with an IC50 value of 15 nM. PRMT5-IN-47 shows antiproliferative activity. PRMT5-IN-47 shows anticancer activity .
    PRMT5-IN-47
  • HY-162783

    Histone Methyltransferase Cancer
    AZ-PRMT5i-1 (Compound 28) is an effective and orally active MTAP-selective PRMT5 inhibitor. AZ-PRMT5i-1 also demonstrates MTA cooperativity and exhibits both in vitro and in vivo antitumor activities, and can be used to study MTAP-deficient cancers .
    AZ-PRMT5i-1
  • HY-16938
    5'-Methylthioadenosine
    5 Publications Verification

    5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine

    Endogenous Metabolite Apoptosis Parasite Metabolic Disease Cancer
    5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis . 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis .
    5'-Methylthioadenosine
  • HY-16938R

    5'-(Methylthio)-5'-deoxyadenosine (Standard); 5'-Deoxy-5'-(methylthio)adenosine (Standard); 5'-S-Methyl-5'-thioadenosine (Standard)

    Reference Standards Endogenous Metabolite Apoptosis Parasite Metabolic Disease Cancer
    5'-Methylthioadenosine (Standard) is the analytical standard of 5'-Methylthioadenosine. This product is intended for research and analytical applications. 5'-Methylthioadenosine (5'-(Methylthio)-5'-deoxyadenosine) is a nucleoside generated from S-adenosylmethionine (SAM) during polyamine synthesis[1]. 5'-Methylthioadenosine suppresses tumors by inhibiting tumor cell proliferation, invasion, and the induction of apoptosis while controlling the inflammatory micro-environments of tumor tissue. 5'-Methylthioadenosine and its associated materials have striking regulatory effects on tumorigenesis[2].
    5'-Methylthioadenosine (Standard)
  • HY-N0086R

    6-Methyladenosine (Standard); N-Methyladenosine (Standard)

    Endogenous Metabolite Influenza Virus Reference Standards Infection
    N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
    N6-Methyladenosine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: